Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BD Introduces New Automated Erythrocyte Sedimentation Rate Instrument

Published: Wednesday, December 11, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
BD Sedi-20 & BD Sedi-40 help improve accuracy and patient outcomes.

BD Diagnostics has introduced two new erythrocyte sedimentation rate (ESR) instruments in Europe that standardize analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.

Erythrocyte sedimentation is a commonly used hematology test to measure inflammation and the presence and severity of disease. “Improved automation and efficiency are key to carrying out analytical tests in a busy laboratory. More and more tests are being conducted each year and reduced healthcare spending puts pressure on laboratory resources,” comments Stephen Church, European Medical Affairs, BD Diagnostics -Preanalytical Systems.

Manual ESR testing has the potential for errors during the analytical process. The new BD Sedi-20 and BD Sedi-40 combined with BD Seditainer™ tube technology, standardize analysis to improve accuracy. The BD Sedi-40 has an integrated barcode reader and tube mixer.

The barcode reader ensures fast, accurate entry of sample identification information. Sample misidentification is one of the many errors which can occur during the preanalytical phase. The integrated mixer ensures consistent and standardized mixing of the sample, which is critical in order to obtain an accurate result.

Moving from an open manual process to an automated closed process will improve healthcare worker safety by reducing the risk of exposure to blood-borne pathogens.

With an analysis time of just 30 minutes, a 50% reduction in time to result is achieved compared to the gold standard of one hour with Westergren.

BD Sedi-20 can perform 20 tests an hour and the BD Sedi-40 can perform 40 tests an hour. The BD Sedi-40 can be connected to a laboratory information system to enable automatic uploading of results.

BD Sedi-20 and Sedi-40 are being made available in Europe.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BD Diagnostics MRSA Assay Receives FDA Clearance
Company receives FDA clearance to market the BD MAX™ MRSA XT Assay for use on the fully-automated BD MAX™ System.
Tuesday, January 14, 2014
BD Diagnostics Receive FDA Clearance for StaphSR Assay
BD has received FDA clearance to market the BD MAX™ StaphSR Assay for use on the fully-automated BD MAX™ System.
Tuesday, December 03, 2013
BD announces award to NHS Supply Chain Framework Agreement
New award to the national framework agreement for Microbiology generates interest.
Monday, December 10, 2012
Nationwide Educational Tour Kicks Off on the Future of Molecular Diagnostics
BD Diagnostics convenes experts to address pressing topics for clinical laboratory professionals. Focus will be on the growing role of molecular diagnostics in women’s health, as well as advances in its implementation in the clinical laboratory.
Monday, March 05, 2012
BD Diagnostics Expands Portfolio with Automated Instrumentation Technologies
Company announced the expansion of its microbiology portfolio to include new automated instrumentation technologies that will enable the Company to offer innovative total lab automation solutions to hospitals and laboratories worldwide.
Thursday, February 16, 2012
Scientific News
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!